Eleanor Barnes is Professor of Hepatology and Experimental Medicine, leading a research group in applied immunology relevant to liver disease. She has a long standing interest in hepatotrophic viruses, viral pathogenesis, immunology and vaccine development. She has led early human experimental medicine studies with the aims of developing a prophylactic HCV vaccine, including 2nd generation HCV vaccines based on conserved viral genomes, and constructs that encode genetic adjuvants with the potential for wide applicability in cancer and infectious disease. She is also developing a program in HBV using adenoviral vectored vaccines for HBV immunotherapy for use in combination with check point modulators. She has played a leading role in evaluating COVID19 vaccines in immune suppressed patients and using single cell and RNA sequencing technologies to further understand the immune perturbations in these patients. At the 2023 HBV cure meeting, she will give an overview of the immune profiles generated by therapeutic vaccines.
